Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Oak Associates Ltd. OH

Oak Associates Ltd. OH increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,771 shares of the pharmaceutical company’s stock after purchasing an additional 200 shares during the quarter. Oak Associates Ltd. OH’s holdings in Vertex Pharmaceuticals were worth $2,313,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Aries Wealth Management acquired a new stake in Vertex Pharmaceuticals in the first quarter worth about $293,000. Polar Asset Management Partners Inc. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $22,954,000. Brighton Jones LLC raised its position in Vertex Pharmaceuticals by 45.0% in the first quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company’s stock worth $3,113,000 after acquiring an additional 1,994 shares in the last quarter. GAMMA Investing LLC raised its position in Vertex Pharmaceuticals by 25.1% in the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock worth $2,425,000 after acquiring an additional 1,005 shares in the last quarter. Finally, Stanley Laman Group Ltd. bought a new stake in Vertex Pharmaceuticals in the first quarter worth about $486,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on VRTX shares. Canaccord Genuity Group dropped their price target on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating on the stock in a research report on Wednesday, August 6th. HC Wainwright dropped their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. Leerink Partnrs cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. Wall Street Zen cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Finally, UBS Group set a $553.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $497.10.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.5%

NASDAQ VRTX opened at $389.08 on Thursday. The stock’s 50-day moving average price is $435.47 and its two-hundred day moving average price is $459.64. The company has a market cap of $99.76 billion, a PE ratio of 27.81 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.